ALS Diagnosis Biomarkers CSF Analysis Segmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing and monitoring amyotrophic lateral sclerosis (ALS) are inadequate, lacking effective therapeutic targets and reliable biomarkers for disease progression and survivability, with existing biomarkers showing limited efficacy in clinical settings.
Innovation Solution
The use of specific biomarkers such as C-reactive protein (CRP), cystatin C, plasminogen, complement C3, CysGly-transthyretin, and phosphorylated neurofilament heavy chain (pNFH) in cerebrospinal fluid (CSF) to determine ALS onset, progression, and survivability, with established thresholds for diagnosis and treatment monitoring.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If multiple biomarkers are analyzed in CSF samples, then diagnostic accuracy and monitoring capability improve, but test complexity and cost increase
Solution Approach 1:
The patent segments the diagnostic process into multiple independent biomarker measurements (CRP, cystatin C, plasminogen, complement C3, CysGly-transthyretin, and pNFH), each detectable by separate assays. This allows the complex diagnostic task to be divided into manageable components that can be performed sequentially or in parallel, maintaining high diagnostic accuracy while making the overall test protocol more implementable in clinical settings.
2Reliability
If established threshold values are used for biomarker levels, then diagnostic reliability improves, but applicability to diverse patient populations may be limited
Solution Approach 1:
The patent establishes specific threshold values for each biomarker (e.g., CRP ≥ 3.0 ng/ml, cystatin C ≤ 1.5 μg/ml, pNFH ≥ 5.0 ng/ml) that can be applied across different patient populations. These parameter thresholds provide standardized criteria for diagnosis and monitoring, ensuring consistent and reliable interpretation of test results regardless of population variability, while still allowing for clinical judgment in atypical cases.
Data Source
AI summary
Methods for determining the onset of ALS in a subject are provided. One method includes analyzing a sample obtained from the subject for the presence or amount of one or more biomarkers indicative of ALS. In a preferred embodiment, the biomarkers are one or more of the following: C-reactive protein (CRP), cystatin c, plasminogen, complement C3, CysGly-transthyretin, and phosphorylated neurofilament heavy chain (pNFH). The sample is typically cerebral spinal fluid (CSF). The levels or concentrations of the biomarkers can be used to determine the onset of ALS, monitor the progression of ALS, or monitor the progression of a treatment for ALS.